Versartis (VSAR) to Release Earnings on Wednesday
Versartis (NASDAQ:VSAR) will issue its Q4 2017 quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.
Shares of Versartis (VSAR) opened at $1.70 on Tuesday. Versartis has a 52-week low of $1.60 and a 52-week high of $24.00. The stock has a market cap of $60.88, a PE ratio of -0.43 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.
In other news, Director Srinivas Akkaraju bought 419,700 shares of Versartis stock in a transaction on Friday, December 1st. The shares were bought at an average cost of $2.13 per share, with a total value of $893,961.00. Following the completion of the purchase, the director now directly owns 14,955 shares of the company’s stock, valued at $31,854.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jay Shepard sold 14,446 shares of Versartis stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $1.80, for a total transaction of $26,002.80. Following the transaction, the insider now directly owns 602,298 shares in the company, valued at $1,084,136.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,400 shares of company stock worth $38,520. Insiders own 10.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/02/19/versartis-vsar-to-release-earnings-on-wednesday.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.